Two National Groups Partner to Develop Shared IBD Decision-making Program

Two National Groups Partner to Develop Shared IBD Decision-making Program
The Crohn’s & Colitis Foundation and the American Gastroenterological Association (AGA) are collaborating with Pfizer to develop a program that aims to jumpstart advances in the area of shared decision-making in inflammatory bowel diseases (IBDs). The program is designed to identify gaps and needs in effective patient-provider communication and where research not been enough to understand how shared decision-making can prevent suboptimal treatment. The program consists of a national survey of patients and healthcare practitioners to identify gaps in knowledge and use of shared decision-making in IBD, followed by a call for proposals to develop strategies based on the gaps and needs identified. Winning programs will be announced during the summer. The program will culminate in a stakeholder conference with patients and providers to identify innovative solutions, current opportunities and challenges ahead to build an action plan – to be planned and developed between 2017 and 2020. "Partnering with the AGA and Pfizer on such an important project is a natural extension of strong relationships we already have with both organizations," Michael Osso, president and CEO of the Crohn’s & Colitis Foundation, said in a press release. "Working together, we will address the critical need to identify tools and mechanisms to support shared decision-making and improve health communication between patients and providers,” he added. Timothy Wang, MD, American Gastroenterological Association Fellow and president of the AGA, said communication between the physician and the patient is "integral" for IBD patients to receive the care care available. "We are pleased that our work with the foundation and Pfizer will help identify new ways to facilitate these
Subscribe or to access all post and page content.